Shared Decision Making on Radiation Dose for Lung Malignancies

Launched by VEJLE HOSPITAL · Jun 17, 2021

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to help patients with lung cancer make decisions about their treatment. The study focuses on using a special tool called a Patient Decision Aid (PtDA) that was created with input from patients. This tool is designed to help patients and their doctors discuss and agree on the best dose of a specific type of radiation therapy called stereotactic body radiation therapy (SBRT) for lung tumors that are very close to the chest wall. By using the PtDA, the goal is to make sure patients feel more involved and informed about their treatment choices.

To participate in this trial, individuals must be at least 18 years old and have a confirmed or likely diagnosis of non-small cell lung cancer or cancer that has spread to the lungs, with tumors that are 1 cm or smaller from the chest wall. They should also be eligible for the specific radiation treatment and able to understand the information provided in Danish. Participants can expect a collaborative experience where they can actively discuss their treatment options with their healthcare team. It’s important to note that people who have had previous radiation therapy in the chest area may not be eligible for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Histologically confirmed or high probability of non-small cell lung cancer, or metastasis from other cancer, located ≤ 1 cm from the thoracic wall. High probability refers to consensus on the diagnosis at the local multi-disciplinary lung tumor conference.
• • Eligible for stereotactic body radiation therapy in ablative doses (i.e. 66/45 Gy in 3 fractions) following national guidelines (2).
• • Can read and understand Danish.
• • Written and orally informed consent.
• • Performance status 0-2
• • Life expectancy \> 6 months assessed by the physician during the consultation.
• Exclusion Criteria:
• • Previous radiation therapy in the thoracic region (lung, breast or mediastinum), if it is not possible to produce a new radiation plan of 66 or 45 Gy in 3 fractions that considers previous radiation therapy and still complies with all constraints, including dose to the thoracic wall. Previous surgery in the thorax is allowed.
• • Mental or social conditions preventing full understanding of the information or the planned treatment and follow-up.